Clinical trials
Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 5,670 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07312292RecruitingPhase 2
Radioembolization with angiotensin II to boost tumor radiation dose
This trial tests whether adding a drug called angiotensin II (which tightens blood vessels in healthy tissue) during radioembolization can deliver more radiation directly to liver tumors. It is for people who have liver tumors (either primary or that have spread to the liver) and are scheduled for radioembolization.
Utrecht, UtrechtAges 18 years+ - NCT07339085Recruiting
Advanced MRI for brain tumor recurrence or radiation damage
This study uses advanced MRI scans to better tell the difference between a returning brain tumor and radiation injury. It may help guide your treatment decisions.
Los Angeles, CaliforniaAges 18 years+ - NCT07343791RecruitingEarly Phase 1
DC-CIK cell therapy plus three drugs for advanced colorectal cancer
This trial tests a combination of immune cells (DC-CIK) and three cancer drugs (epaloliposide, vortexil, and regorafenib) as a third-line treatment for people with advanced colorectal cancer that has spread. It aims to see if this mix is safe and helps shrink tumors or slow the cancer's growth.
Nanjing, JiangsuAges 18–75 - NCT07079631RecruitingPhase 1/Phase 2
Testing BNT314 with pumitamig and chemo for advanced colorectal cancer
This trial tests a new combination of drugs (BNT314 and pumitamig) plus chemotherapy for people with advanced colorectal cancer that has not responded to prior treatments. The goal is to see if this combination is safe and helps shrink or control the cancer.
New Haven, ConnecticutAges 18 years+ - NCT07431281RecruitingPhase 3
New drug combo for advanced stomach cancer with CLDN18.2
This trial tests a new drug combination for people with advanced stomach cancer that has not been treated before. It looks at two groups: one with PD-L1 (a protein that helps decide if immunotherapy works), and one without. The treatment includes an antibody-drug conjugate (Sonesitatug Vedotin) plus standard chemotherapy, with or without an immunotherapy drug.
Mobile, AlabamaAges 18 years+ - NCT07379268Recruiting
Anti-HER2 drug for advanced bladder cancer
This trial tests an antibody-drug conjugate that targets HER2 in people with advanced bladder cancer that has spread or cannot be removed by surgery. It is for patients whose cancer has not responded to or stopped responding to platinum-based chemotherapy.
Jinan, ShandongAges 18–80 - NCT02819882Recruiting
Registry study for advanced or metastatic breast cancer
This study collects health and treatment information from people with breast cancer that cannot be fully removed by surgery or that has spread to other parts of the body. It may help researchers better understand which treatments are used and how people do over time.
Elche, AlicanteAges 18 years+ - NCT03125642RecruitingPhase 2
Auto stem cell transplant for lymphoma after chemo
This Phase 2 study tests an auto (self) stem cell transplant for people with certain types of non-Hodgkin lymphoma or Hodgkin lymphoma who respond to chemotherapy (they are “chemo-sensitive”). It may help some patients get a deeper or longer remission by resetting the bone marrow after high-dose treatment.
Minneapolis, MinnesotaAges Up to 75 years - NCT03179540Recruiting
Watch-and-wait treatment after rectal cancer radiation
This trial looks at a “non-surgery” approach for some people with locally advanced rectal cancer who respond very well to radiation plus chemotherapy. If your cancer shows a complete clinical response on follow-up checks, the study may help you avoid an immediate major operation while closely monitoring you.
Toronto, OntarioAges 18 years+ - NCT07417488RecruitingPhase 1
Vaccine therapy for advanced colorectal and small bowel cancer
This trial tests a vaccine therapy for people with advanced colorectal or small bowel cancer that has spread or can't be removed. The vaccine targets a protein found on cancer cells to help your immune system fight the cancer.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07425054RecruitingPhase 2
Chemoradiation with or without immunotherapy for anal cancer
This trial tests whether adding an immunotherapy drug (retifanlimab) to standard chemoradiation improves outcomes for people with locally advanced anal cancer. The treatment is adjusted based on HPV DNA levels in your blood.
Cleveland, OhioAges 18 years+ - NCT07455032RecruitingPhase 1
Neoadjuvant therapy combo for head and neck cancer
This trial tests a combination of two drugs (CADI-05 and pembrolizumab) before surgery for people with a certain type of head and neck cancer that hasn't spread. The goal is to see if this treatment can help shrink the tumor before it is removed.
Philadelphia, PennsylvaniaAges 18 years+ - NCT07461454RecruitingPhase 3
Comparing YL202 to other treatments for HR+/HER2- breast cancer
This trial tests a new drug called YL202 against other treatments chosen by your doctor for people with a certain type of advanced breast cancer (HR+/HER2-). It aims to see if YL202 works better. You may join if your cancer has spread, you've already tried chemotherapy, and you meet other health criteria.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07463573RecruitingPhase 3
New drug vs chemotherapy for advanced esophageal cancer
This trial tests a new drug, QLC5508, against standard chemotherapy for people with advanced esophageal cancer that has already been treated. It aims to see if the new drug works better.
Beijing, Beijing MunicipalityAges 18 years+ - NCT07471776RecruitingPhase 2
Predicting ADC treatment response with PET scans in advanced breast cancer
This study uses special PET scans to see if a type of targeted therapy called an anti-TROP2 ADC will work well for your advanced breast cancer. The therapy is already part of your standard care; the scans help doctors understand how your tumor responds.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07506057RecruitingPhase 2
Trastuzumab, serplulimab, and chemo for advanced bile duct or bladder cancer
This trial tests a combination of trastuzumab (a HER2-targeted drug), serplulimab (an immunotherapy), and chemotherapy for people with advanced bile duct or bladder cancer that is HER2-positive and has not responded to prior treatments. The goal is to see if this mix can shrink tumors or slow the disease.
Shenyang, LiaoningAges 18–85 - NCT07510828RecruitingPhase 1/Phase 2
CAR-NK cells for advanced solid tumors
This trial tests whether specially engineered NK cells can find and attack your type of cancer. It is for people with advanced solid tumors that haven't responded to standard treatments.
Shenzhen, GuangdongAges 18–75 - NCT07553572Recruiting
Smartphone app to track cancer symptoms during treatment
This study tests a smartphone application designed to help you monitor and manage side effects and symptoms while you're receiving chemotherapy or other systemic treatment for breast cancer, colorectal cancer, or lymphoma. The app may help your doctors catch problems early and support you throughout your treatment.
Boston, MassachusettsAges 18 years+ - NCT07563595Recruiting
Elacestrant for advanced ER+ HER2- breast cancer with ESR1 mutation
This trial tests elacestrant, a new hormone therapy drug, in women whose advanced or spread breast cancer has stopped responding to first-line hormone treatment. The drug is designed to work against a specific genetic change (ESR1 mutation) that can develop in these cancers.
Freiburg im BreisgauAges 18 years+ - NCT07595835RecruitingPhase 1/Phase 2
Radioactive particles injected into pancreatic tumors
This trial tests a new treatment where doctors use imaging to guide radioactive particles directly into locally advanced pancreatic cancer tumors that haven't spread. The goal is to shrink or control the cancer with radiation delivered right to the tumor.
Amsterdam, North HollandAges 18 years+ - NCT07614061RecruitingPhase 1
Cell therapy for advanced bile duct cancer
This trial tests a new treatment called BTC-Ag-T, which uses your own immune cells enhanced in the lab to fight advanced biliary tract cancer (cancer of the bile ducts or gallbladder). It's designed for patients whose cancer has spread or cannot be surgically removed and who have already received standard chemotherapy plus immunotherapy.
ShanghaiAges 18 years+ - NCT07638371RecruitingPhase 1
MSK-TCR5 Cell Therapy for RAS G12D Solid Tumors
This study tests a new type of cell therapy called MSK-TCR5, designed to fight solid cancers (like pancreatic, lung, or colon cancer) that have a specific RAS G12D mutation. The therapy uses your own immune cells trained to recognize and attack cancer cells with this mutation.
Basking Ridge, New JerseyAges 18 years+ - NCT03907475RecruitingPhase 2
Durvalumab with chemotherapy for advanced solid tumors
This trial studies durvalumab (an immune therapy) combined with chemotherapy to treat advanced solid tumors that have grown despite prior standard treatment or have no proven standard option. It aims to improve control of the cancer and help people live longer.
Bethesda, MarylandAges 18 years+ - NCT06834373RecruitingPhase 2
Golcadomide and rituximab before CAR T for lymphoma
This trial tests a combination of two medications (golcadomide and rituximab) as a short-term treatment to shrink lymphoma before you receive CAR T-cell therapy. The goal is to make the CAR T treatment more effective for people whose lymphoma has come back or hasn't responded to previous treatments.
Scottsdale, ArizonaAges 18 years+
Hear when a new Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 5,670 recruiting advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
- Locally Advanced Non-Small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.